Hashmi Health Care Launches New High-Quality Unit to Build up Diabetes Treatment

(prHWY.com) April 12, 2012 - Amroha, India -- Nearly 10 million Indians are now diabetic--triple the 2011 rate. If current trends continue, 25 million Indians adults will be living with diabetes by the end of 2015.Now a new approach to supplementary those afflicted with Diabetes, with an effective supplement based on herbal Medicine.

Hashmi Health care announced today that the first diabetes patient has commenced treatment in diabetes exacerbation study, marking the start of the Phase III clinical development program with this once daily dose, for this serious and chronic disease.

Operating under a lean structure, Dr Hashmi, President of Hashmi Health care, will lead this new operation, working closely with Mr. Ayaz Uddin, Hashmi Health Care Senior Vice President. The new unit will seek to leverage existing capabilities and partnerships and establish further in-licensing opportunities. The new diabetes treatment will assess the potential benefit of the combination of natural herbs and research scientific herbs the component products and existing treatments for diabetes.

The new treatment will consist of range of natural extract herbs to determine the efficacy and safety of diabetes patients who remained uncontrolled on current treatment. The initiation of this type of treatment would helps to control the blood sugar level. As part of the agreement with Hashmi Health care manufacturer of herbal products, Hashmi Health has obtained global rights to a number of diabetes treatment medicines that could, upon approval, be used to treat diabetes symptoms, diabetes causes and control blood sugar level.

Dr. Hashmi, President of Hashmi Health care, said: "In addition to our existing discovery effort, alternative opportunities need to be explored to make treatments available for diabetes and rare diseases. This complementary approach will combine our existing global expertise with specialist partners .Overtime, this new unit has the potential to deliver multiple therapies responding to high medical needs of underserved populations of patients."

Mr. Ayaz Uddin Hashmi, Senior Vice President of Hashmi Health Care said "The entry into this new strategy of diabetes treatment to deliver more products of value and improve returns in R&D through a focus on areas with a higher probability of success. The risk associated with product discovery and development in rare diseases is generally lower than other disease areas as disease definitions are very clear and clinical trials tend to be small with robust endpoints."

###